Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:40 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], I[email protected]
